Definiens, Cernostics to develop cancer diagnostic tests
Definiens and Cernostics have entered a partnership to develop a multiplexed assay tool for the diagnosis of cancer.

Cernostics takes a systems approach to tumor analysis, evaluating immune, stromal, stem cell and tumor biomarkers on a single slide while preserving tissue structure. This can help clinicians better understand disease subtypes and help them choose the course of treatment most suited to each patient’s disease state, said Danville, Pa.-based Cernostics.

Cernostics will be using Munich-based Definiens Tissue Studio to develop its cancer diagnostic test, which relies on multiplexed panels of fluorescence biomarkers, added the company.